. Role for PKC in the adenosine-induced decrease in shortening velocity of rat ventricular myocytes. Am J Physiol Heart Circ Physiol 279: H2685-H2693, 2000.-We previously demonstrated that both adenosine receptor activation and direct activation of protein kinase C (PKC) decrease unloaded shortening velocity (V max ) of rat ventricular myocytes. The goal of this study was to further investigate a possible link among adenosine receptors, phosphoinositide-PKC signaling, and V max in rat ventricular myocytes. We determined that the adenosine receptor agonist R-phenylisopropyladenosine (R-PIA, 100 M) and the ␣-adrenergic receptor agonist phenylephrine (Phe, 10 M) increased turnover of inositol phosphates. PKC translocation from the cytosol to the sarcolemma was used as an indicator of PKC activation. Western blot analysis demonstrated an increased PKC-ε translocation after exposure to R-PIA, Phe, and the PKC activators dioctanoylglycerol (50 M) and phorbol myristate acetate (1 M). PKC-␣, PKC-␦, and PKC-did not translocate to the membrane after R-PIA exposure. Finally, PKC inhibitors blocked R-PIA-induced decreases in V max as well as Ca 2ϩ -dependent actomyosin ATPase in rat ventricular myocytes. These results support the conclusions that adenosine receptors activate phosphoinositide-PKC signaling and that adenosine receptor-induced PKC activation mediates a decrease in V max in ventricular myocytes.
THE PHOSPHATIDYLINOSITOL-PHOSPHOINOSITIDE signaling pathway in the myocardium can be activated by ␣-adrenergic (42) , ANG II (1), and -opioid (40) receptor agonists. In this signaling pathway, receptor-coupled G proteins activate phospholipase C, which in turn catalyzes hydrolysis of phosphatidylinositol bisphosphate [PtdIns(4,5)P 2 ] into diacylglycerol and inositol (1, 4, 5) trisphosphate [Ins(1,4,5)P 3 ]. Ins(1,4,5)P 3 acts to liberate Ca 2ϩ from intracellular storage sites, and diacylglycerol activates protein kinase C (PKC). Activation of PKC involves translocation of inactive PKC from the cytosol to the cell membrane where diacylglycerol activates it. In addition, some PKC isoforms require the presence of Ca 2ϩ (19) . The PKC-ε isoform appears to be the predominant isoform of PKC in adult rat ventricular myocytes; PKC-␣, PKC-␦, and PKC-are also observed (3, 33) . Upon activation, PKC-ε has been shown to translocate to cardiac myofilaments (9, 20) . PKC activation in the myocardium has been associated with phosphorylation of the myofilament proteins C protein, troponin I, and troponin T in vitro (22) and increased phosphorylation of a 15-kDa sarcolemma protein, a 28-kDa cytosolic protein (37) , and myosin light chain 2 (7) in vivo. Previous work has suggested phosphorylation of troponin I by PKC-εdecreases Ca 2ϩ -dependent actomyosin ATPase (21) .
Activation of adenosine receptors mediates decreases in heart rate (30) and developed pressure (5) and protects the heart from ischemic damage (38) . In myocardial preparations, adenosine has been shown to decrease the velocity of unloaded shortening (V max ) (26, 36) and activate ATP-sensitive K ϩ channels (43) . Studies suggest that adenosine receptors may be coupled to the activation of PKC in smooth muscle (13) . However, adenosine has also been shown to decrease adenylate cyclase activity in the myocardium (34) . In a previous study, we found the adenosine agonist Rphenylisopropyladenosine (R-PIA) and the diacylglycerol analog dioctanoylglycerol (diCg) decrease V max to the same extent in isolated rat ventricular myocytes (26) . This suggests the functional effects of activation of the adenosine receptor may be mediated by activation of the phospholipase-PKC signaling pathway. Therefore, the purpose of the present study was to determine whether adenosine receptors are coupled to the phosphoinositide pathway and whether activation of PKC is the basis for a decrease in V max in isolated ventricular myocytes.
MATERIALS AND METHODS

Biochemical Assays
Ins (1, 4, 5 )P 3 assay. Cells were isolated as described by Lester and co-workers (26) . Treatment groups were the following: control, 10 M phenylephrine (Phe, ␣-agonist), and 100 M R-PIA. R-PIA is an A 1 -and A 3 -receptor agonist, and treatment with 100 M R-PIA ensures activation of both A 1 and A 3 receptors, which have affinities of 1.17 and 1,210 nM, respectively (27) . Only isolations showing a positive Phe response Ն1.15 times control were included in the analysis because ␣-adrenergic stimulation is known to liberate Ins(1,4,5)P 3 in ventricular myocytes (4).
To prepare samples for Ins(1,4,5)P 3 determination, cells were exposed to drugs or vehicle for 1 min, and the reactions were stopped by adding a 5:1 dilution of 1 M trichloroacetic acid or a 0.2:1 dilution of 100% trichloroacetic acid to cells. In early experiments the suspension was homogenized, but this was deemed unnecessary in later experiments. Samples were incubated on ice for 15 min. After 1 min of centrifugation (10,000 g), the supernatant was decanted and incubated for 15 min at room temperature. Trichloroacetic acid was extracted from samples by adding a 3:1 dilution of 1,1,2-trichloro-1,2,2-trifluoroethane and trioctylamine in a 2:1 solvent-to-sample ratio. After 15 s of mixing, samples were incubated for 3 min. The aqueous layer was removed and frozen at Ϫ80°C.
The Ins(1,4,5)P 3 3 H-Radioreceptor Assay Kit from NENDuPont was used to determine Ins(1,4,5)P 3 levels. The kit is supplied with a preparation of calf cerebellum membrane containing Ins(1,4,5)P 3 receptor, [ 3 H]Ins(1,4,5)P 3 , and appropriate buffers. The kit has a sensitivity range of 0.12-12.0 pmol/100 l of sample. The assay is based on Ins(1,4,5)P 3 from experimental samples displacing known concentrations of labeled Ins(1,4,5)P 3 bound to the membrane-receptor preparation. Bound radioactivity in the experimental samples is then compared with a standard curve to determine Ins(1,4,5)P 3 levels.
PKC isoform translocation. Cells were prepared as described by Lester and co-workers (26) and incubated for 5 min with 10 M Phe, 100 M R-PIA, 50 M diCg (a PKC activator), or 1 M phorbol-12-myristate-13-acetate (PMA). PMA at a 1 M concentration is known to activate PKC in addition to other second messengers. After drug treatment, samples were centrifuged, and pellets were frozen at Ϫ80°C. Membrane fractions of cells were isolated using the protocol described by Puceat and colleagues (33) .
Samples were run on SDS polyacrylamide gels using 5% acrylamide stacking gels and 12% acrylamide resolving gels. Gel proteins were transferred to polyvinylidene difluoride (PVDF) membranes. Immunoblotting was performed as described in a protocol included with chemiluminescent reagents (NEL-102, NEN-DuPont). The primary antibodies anti-PKC-ε (1:100 dilution; GIBCO-BRL, Grand Island, NY), anti-PKC-␦ (1:500 dilution; Transduction Labs, Lexington, KY), anti-PKC-␣ (1:1,000 dilution; Transduction Labs), anti-PKC-(1:1,000 dilution; Transduction Labs), and peroxidaseconjugated secondary antibody (1:4,000 dilution; Sigma, St. Louis, MO) were utilized. Membranes were incubated in chemiluminescent reagents and exposed to X-ray film. PVDF blots were also stained with india ink to establish protein load and relative amount of protein transferred for each sample. Staining of the blot and normalizing to relative protein load were necessary to control for variations in gel loading and transfer. Such variations can ultimately lead to apparent changes in PKC content (31) .
Densities of PKC isoform bands from X-ray film and densities of india ink stain of an ϳ46 kDa protein from corresponding PVDF blots were determined using National Institutes of Health Image software. PKC density was weighted to the corresponding protein transferred on each lane (31) . To do this, the average density of the india ink stain for the 46-kDa protein was obtained, and the ratio of density of the 46-kDa protein on a given lane to the average density of the 46-kDa protein was calculated. This value indicates the relative protein transferred onto a given lane of a blot. The density of the PKC band on each lane of the X-ray was also normalized to the average density of PKC of control-treated cells and then multiplied by the relative protein transferred onto the blot. When the PKC contents from multiple measurements were obtained, the normalized PKC band densities were averaged to give a single value for that myocyte isolation and treatment group. Only isolations with a positive Phe response were used in analysis because ␣-adrenergic stimulation is known to activate PKC translocation (33) .
Actomyosin ATPase. Cells were prepared as described by Lester and co-workers (26) and treated with 100 M R-PIA, 500 M 8-sulfophenyltheophylline (8-SPT), R-PIA plus 8-SPT, 10 M chelerythrine (Chel), 100 M R-PIA plus 10 M Chel, 100 nM bisindolylmaleimide I (Bis), or 100 nM Bis plus 100 M R-PIA. 8-SPT is an adenosine receptor antagonist; Chel and Bis are PKC inhibitors. Chel was used at 10 M because the concentration required for 50% inhibition (IC 50 ) of PKC is 0.7 M, and IC 50 values are 0.17 mM for PKA and 0.1 mM for tyrosine kinase and the Ca 2ϩ -calmodulin-dependent kinase (16) . Chel inhibits PKC by binding to the substrate binding site of PKC (16) , whereas Bis inhibits PKC by binding to the ATP binding site on PKC (39) . Chel (1 M) has been shown to inhibit PKC-ε translocation in the rat myocardium (24) . Bis (50 nM) has been shown to inhibit the PKC-␣-, PKC-␦-, and PKC-ε-dependent phosphorylation of proteins in the particulate fraction of the ischemic rat myocardium (2) .
Myocytes isolated from a given heart were used in one of the following studies, each of which was divided into three study groups:
2): control, R-PIA, Chel, Chel plus R-PIA; and 3): control, R-PIA, Bis, Bis plus R-PIA. PKC inhibitors and 8-SPT were added 3 min before the addition of R-PIA. R-PIA treatment was for 5 min. All groups had an equal amount of DMSO.
After drug treatment, myofibrils were isolated from cells based on the procedures of Murphy and Solaro (28) . During myofibrillar isolation, all solutions contained 100 nM calyculin A to inhibit phosphatase activity and help maintain phosphorylations induced by the original drug treatment of cells. Once myofibrils were isolated, 30-240 g of protein was added to ATPase assay buffers, either pCa 9.0 or pCa 4.0, containing the following (in mM): 2 EGTA, 20 imidazole, 3 NaATP, and 5 MgCl 2 and KCl to give a constant ionic strength of 60 mM (pH 7.0). The ATPase assay was carried out for 12 min at 32°C before the reaction was stopped with 20% trichloroacetic acid. P i was measured using the method of Fiske and Subarrow (12) . P i release was found to be linear with time under the conditions stated (data not shown).
V max of Ventricular Myocytes
Cell preparation. Cells were isolated as described by Lester and co-workers (26) and divided into control, 100 M R-PIA, 10 M Chel, and 100 M R-PIA plus 10 M Chel treatment groups. The 10 M Chel and 100 M R-PIA plus 10 M Chel groups were pretreated with Chel for 3 min. After Chel pretreatment, R-PIA was added to the R-PIA and R-PIA plus Chel groups, and control cells were treated with vehicle. All groups were then incubated for 5 min at room temperature. After drug treatment, cells were exposed to 0.3% ultrapure Triton X-100 in relaxing solution (see Solutions) for 5 min to disrupt all lipid membranes. Cells were then washed in relaxing solution and stored on ice for immediate use. Cells were used up to 48 h postisolation.
For this portion of the study, initial isolations were performed using type 4 collagenase (Worthington lot S2P350N), and later isolations were performed using type 2 collagenase (Worthington lot 45P862). Because we had no experience with collagenase lot 45P862, a positive control for intact receptor-signal transduction pathways was included in isolations performed with this collagenase. Cells were treated with the ␤-adrenergic receptor agonist isoproterenol (100 nM), because ␤-adrenergic receptor activation is well known to decrease the Ca 2ϩ sensitivity of tension of ventricular myocytes. Only isolations showing a ␤-adrenergic-dependent decrease in the Ca 2ϩ sensitivity of tension were included in the final analysis of V max .
Myocyte attachment and experimental apparatus. Myocytes were attached via glass pipettes to a force transducer (model 403, Cambridge Technology, Watertown, MA) and a piezoelectric translator (model 173, Physik Institute, Waldbronn, Germany) using Great Stuff foam insulation (InstaFoam, Marietta, GA) as the adhesive (17, 26) . Sarcomere lengths were adjusted to ϳ2.1-2.3 m as judged by Filar micrometer. Myocytes were maximally activated in a pCa 4.5 (pCa ϭ Ϫlog[Ca 2ϩ ]) solution and relaxed in a pCa 9.0 solution. Photographs were taken of a given myocyte in both pCa 4.5 and 9.0 solutions to assess change in sarcomere length and to determine the exact length between pipettes (L o ) and cell width. Cell width was averaged from three measurements taken from each photomicrograph at positions near the center of the length of the cell and 5-10 m from the tips of the two attachment micropipettes.
Measurement of unloaded shortening velocity. The slacktest method was used to determine V max of cardiac myocytes (10, 18) . In brief, cardiac myocytes were activated in pCa 4.5 solution, and, after developing a steady tension, a shortening length step was introduced. Shortening steps fully unloaded the cells such that the tension initially fell to zero. Once the introduced slack was taken up, tension redevelopment began. The cell was then returned to a solution containing a nonactivating level of Ca 2ϩ , pCa 9.0. Each cell underwent four to eight shortening steps of different lengths in a pCa 4.5 solution. To more clearly define the exact time point of tension redevelopment, tension records from a shortening step in pCa 9.0 and pCa 4.5 solutions were computer overlaid. The point at which these tension tracings diverged was taken as the onset of tension redevelopment.
For a given cell, each length of shortening step (m) was plotted versus the corresponding time to onset of tension redevelopment or duration of unloaded shortening (ms). The least-squares method was used to fit a straight line to the data. The slope was then divided by L o to calculate the velocity of shortening in muscle lengths per second (ML/s). Cells meeting the following criteria were included in cumulative velocity analysis: final value of pCa 4.5 tension/initial pCa 4.5 tension Ͼ0.70, goodness of fit to a straight line Ն0.80, change in sarcomere length Ͻ0.15 m, and y-intercept percentage Ͼ5% of L o .
Solutions
Ringer solution contained (in mM) 1.2 MgCl 2 , 4.8 KCl, 118 NaCl, 2 KH 2 PO 4 , 5 pyruvate, 25 HEPES, 11 glucose, and 1 insulin (pH 7.4). The relaxing solution used to wash cells after isolation had a pCa of 9.0 and contained (in mM) 100 KCl, 10 imidazole, 1 MgCl 2 , 2 EGTA, and 4 ATP (pH 7.0). Solutions containing varied concentrations of free Ca 2ϩ were used to activate skinned cells. Free-Ca 2ϩ concentrations ranged from pCa 4.5 to pCa 9.0 and were calculated using the computer program of Fabiato (11) 
Statistical Analysis
ANOVA and t-test were performed (Systat, Evanston, IL) to determine whether average, normalized PKC isoform band densities or Ins(1,4,5)P 3 values of treatment groups were significantly different from 1, i.e., control. For V max studies, groups were subjected to an ANOVA and a t-test to determine differences. The level of significance was considered to be P Ͻ 0.05 in each analysis.
RESULTS
To establish whether adenosine receptor stimulation activates the phosphatidylinositol signaling pathway in ventricular myocytes, we examined the effects of 10 M Phe (␣-adrenergic receptor activation) and 100 M R-PIA (adenosine-A 1 and -A 3 receptor activation) treatment to increase Ins(1,4,5)P 3 levels normalized to untreated cells. The average Ϯ SE control concentration of Ins(1,4,5)P 3 was 9.04 Ϯ 2.67 pmol/mg protein. Treatment with Phe or R-PIA resulted in a significant increase in Ins(1,4,5)P 3 production relative to this control (Fig. 1) .
Inactive PKC-ε is found in the cytosol, and membrane association is necessary for PKC-ε activation (19) . Differential centrifugation and immunoblotting techniques were used to detect translocation of PKC-ε from the cytosol to the membrane and indirectly demonstrate PKC activation. Positive control experiments demonstrated that treatment with the phorbol ester PMA results in decreased cytosolic PKC-ε and increased membrane-associated PKC-ε (Fig. 2) . Translocation of PKC-ε to the membrane fraction was also observed with 10 M Phe, 50 M diCg, and 100 M R-PIA treatment of isolated ventricular myocytes. A Values from three hearts were normalized to control and expressed as means Ϯ SE; *P Ͻ 0.05 vs. control. typical immunoblot of membrane-bound PKC-ε is shown in Fig. 3 . Blots were also stained with india ink to establish the relative protein level transferred. Although the initial protein concentration loaded onto a gel and the transfer conditions were identical, some variability in the amount of protein that was ultimately transferred to the blots existed. As such, PKC-ε density for a given lane on the immunoblots was weighted to reflect protein transferred onto that lane (31) . For example, in Fig. 3 , for Phe treatment, the final membrane-bound PKC-ε would be recorded as 145% [(158 ϫ0.99) ϩ (140 ϫ0.95)/2] relative to control for this isolation. Figure 4 presents the final average membrane-bound PKC-ε relative to control using the various treatments. Treatment with the PKC activators PMA and diCg, the ␣-adrenergic agonist Phe, or the adenosine A 1 and A 3 agonist R-PIA resulted in a significant increase in membrane-associated PKC-ε.
A 5-min exposure to receptor agonists did not alter total immunoreactive PKC-ε content in the intact myocyte measured immediately after drug treatment. Relative total cell PKC-ε under control conditions was 1.00 Ϯ0.08 (n ϭ 12), after R-PIA exposure was 1.00 Ϯ 0.08 (n ϭ 6), after Phe exposure was 1.01 Ϯ 0.08 (n ϭ 6), after diCg exposure was 0.81 Ϯ 0.11 (n ϭ 6, P Ͻ 0.05 compared with control), and after PMA exposure was 1.05 Ϯ 0.16 (n ϭ 6). The small decrease in total immunoreactive PKC-ε after diCg treatment would lead to an underestimate of the diCg-induced increase in the membrane-associated PKC-ε (Fig. 4) .
Western blot analysis of the membrane fractions after R-PIA exposure was also completed using antibodies to PKC-␣, PKC-␦, and PKC-. No significant differences were observed in these isoforms between membranes of untreated and R-PIA-exposed cells. Membranes of R-PIA-treated ventricular myocytes had a PKC-␣ value of 0.93 Ϯ 0.11, a PKC-␦ value of 0.91 Ϯ 0.22, and a PKC-value of 0.83 Ϯ 0.14 relative to membranes from untreated myocytes (n ϭ 6 for all groups). Figure 5 presents photomicrographs of single myocytes in low Ca 2ϩ (pCa 9.0) solution and during maximum activation (pCa 4.5). Among all the treatment groups of control, 100 M R-PIA, 10 M Chel, and 100 M R-PIA plus 10 M Chel, average sarcomere lengths were not significantly different between pCa 4.5 and pCa 9.0 solutions, suggesting a low compliant attachment. Table 1 summarizes the characteristics of cells used to determine V max , including sarcomere length and maximum isometric tension. Maximum isometric tension was not statistically different between any of the drug treatment groups and control (Table 1) . However, the SE of the maximum isometric tension determination accounted for ϳ15% of the total tension; thus small changes in maximum isometric tension may be obscured.
Representative tension traces recorded immediately after various shortening steps during maximum activation are shown in Fig. 6 (see MATERIALS AND METHODS for protocol). As illustrated in Fig. 6 , the duration of unloaded shortening is longer for R-PIA treatment compared with the control and for R-PIA plus Cheltreated cells for nearly identical lengths of cell shortening. The means Ϯ SE V max values for control, 100 M R-PIA-, 10 M Chel-, and 100 M R-PIA plus 10 M Chel-treated cells are shown in Fig. 7 . Treatment with R-PIA significantly decreased V max , and that decrease was blocked by the PKC inhibitor Chel. Chel treatment alone had no effect on V max .
To establish whether the decrease in cross-bridge cycling rate was via the activation of adenosine receptors, isolated ventricular myocytes were treated with 100 M R-PIA, 500 M 8-SPT (an adenosine receptor antagonist nonselective for adenosine receptor sub- type), or R-PIA plus 8-SPT. After drug treatment, myofibrils were isolated from skinned cells. Figure 8A presents the mean Ca 2ϩ -dependent actomyosin ATPase from these various preparations. R-PIA treatment led to a significant decrease in the Ca 2ϩ -dependent myofibrillar ATPase, and this effect was blocked with the addition of 8-SPT.
To further establish whether the R-PIA-induced decrease in cross-bridge cycling rate was through activation of PKC, isolated ventricular myocytes were Fig. 5 . Photomicrographs of enzymatically isolated, agonist-treated, detergent-skinned rat ventricular myocytes. Cells are pictured during relaxation, pCa 9.0 (left), and during maximum activation, pCa 4.5 (right). Sarcomere length was not significantly different between groups or upon exposure to maximum activating levels of Ca 2ϩ . Values presented as means Ϯ SE. n, no. of samples. R-PIA, R-phenylisopropyladenosine; Chel, chelerythrine; y-intercept, y-intercept of magnitude of shortening step vs. duration of unloaded shortening. * P Ͻ 0.05 as compared with control. treated with R-PIA (100 M) and the PKC inhibitors Chel (10 m) or Bis (100 nM). After drug treatment, myofibrils were isolated from skinned cells. Figure 8 , B and C, presents the mean Ca 2ϩ -dependent actomyosin ATPase from these various preparations. R-PIA treatment led to a significant decrease in the Ca 2ϩ -dependent myofibrillar ATPase, and this effect was blocked with the addition of either Chel or Bis.
DISCUSSION
Evidence suggests that adenosine-mediated cardioprotection requires activation of PKC (35) . This implies a link between adenosine receptors, phospholipase C or D activation, and activation of PKC. Therefore, the goal of this study was to establish a link between adenosine receptors and phosphoinositide signaling and functional changes in ventricular myocytes. We found that treatment of isolated ventricular myocytes with the adenosine agonist R-PIA significantly increased turnover of inositol phosphates and led to translocation of PKC-ε. We also demonstrated that the R-PIA-induced decrease in ventricular myocyte V max and myofibrillar actomyosin ATPase could be blocked by PKC inhibitors. Finally, we show that the R-PIAinduced decrease in myofibrillar actomyosin ATPase could be blocked by the adenosine receptor antagonist 8-SPT.
Because myocyte membranes can be damaged during isolation, positive control treatment groups were included in these experiments to demonstrate that known receptor-coupled signaling pathways were intact. ␣-Adrenergic receptor activation increases inositol phosphate turnover (4) and stimulates PKC translocation (33) in the rat myocardium; thus the ␣-adrenergic receptor agonist Phe was used as a positive control in the Ins(1,4,5)P 3 and PKC translocation assays. ␤-Adrenergic receptor PKA activation decreases Ca 2ϩ sensitivity of tension in isolated ventricular myocytes (17) . Thus the ␤-adrenergic-induced decrease in calcium sensitivity of tension was used as a positive control in studies measuring V max .
Activation of the phosphoinositol signaling pathway results in phospholipase C-mediated hydrolysis of PtdIns(4,5)P 2 to Ins(1,4,5)P 3 and diacylglycerol. Diacylglycerol activates conventional and novel isoforms of PKC. We found basal levels of Ins(1,4,5)P 3 at ϳ9 pmol/mg protein. Others have found unstimulated Ins(1,4,5)P 3 concentrations from 4 to 40 pmol Ins(1,4,5)P 3 /mg protein in rat ventricular myocytes (41, 23) . We demonstrated that Ins(1,4,5)P 3 concentrations increased by 25-30% after Phe or R-PIA treatment of ventricular myocytes. The ability of R-PIA to stimulate Ins(1,4,5)P 3 in rat ventricular myocytes has not been previously demonstrated. However, others have shown ␣-adrenergic receptor stimulation increases Ins(1,4,5)P 3 levels by 60% in adult rat ventric- ular myocytes, and R-PIA increased Ins(1,4,5)P 3 concentration by 40% relative to control in guinea pig papillary muscle (25, 41) . We also found that membrane-bound PKC-ε increased by ϳ100% with PMA, 30% with Phe, and 20% with R-PIA treatment relative to control. The ability of R-PIA to stimulate PKC-ε translocation in rat ventricular myocytes has not been previously demonstrated. However, others (3, 33) have reported that PMA treatment increased membranebound PKC-ε by three-to fivefold, and Phe treatment increased membrane-bound PKC-ε almost twofold. Thus our observations of an R-PIA-induced increase in Ins(1,4,5)P 3 and PKC-ε translocation in rat ventricular myocytes are qualitatively consistent with work by others. Our data supports a link between adenosine receptors and phosphoinositide-PKC signaling. It should be noted there is evidence for phospholipase D being coupled to adenosine receptors and PKC activation in smooth muscle cells (13) and whole hearts (8) . The present studies do not eliminate the possibility that adenosine receptor-dependent activation occurs through the phospholipase D pathway.
Previous Western blot analysis of rat adult ventricular myocytes has demonstrated the presence of PKC-␣, PKC-␦, PKC-ε, and PKC-(33) but not PKC-␤ 1 , PKC-␤ 2 , PKC-␥ (33), or PKC-(3). Thus we looked to see whether there was an increase in membrane-bound PKC-␣, PKC-␦, or PKC-with 5 min of R-PIA exposure. No statistical differences were found compared with membranes from untreated cells. Henry and colleagues (15) demonstrated an R-PIA-dependent increase in membrane PKC-␦ by 66 Ϯ 58% (mean Ϯ SE, n ϭ 7, P Ͻ 0.05 vs. controls) at 1 min of R-PIA stimulation of rat ventricular myocytes. However, with 5 min of R-PIA exposure, only an 18% increase of PKC-␦ was observed (15) . This raises the possibility that in the present study a change in membrane-bound PKC-␣, PKC-␦, or PKC-with R-PIA stimulation may have been detected with shorter time exposures to R-PIA.
In a previous study, we found that treatment of isolated ventricular myocytes with R-PIA and the PKC activator diCg resulted in decreased V max (26) . We postulated that the decrease in V max was due to adenosine-mediated activation of PKC. In the present study, we again demonstrated that R-PIA decreases V max . Novel findings of the present study include the observation that the R-PIA-induced decrease in V max is blocked by the PKC inhibitor Chel. In addition, we demonstrated that Ca 2ϩ -dependent actomyosin Mg 2ϩ -ATPase is decreased through activation of adenosine receptors and that this adenosine-induced reduction in cross-bridge cycling can be blocked by PKC inhibitors. This finding is consistent with that of Noland and Kuo (29) , who demonstrated that exposure of cardiac myofibrils to exogenously applied PKC phosphorylates troponin I and results in decreased Ca 2ϩ -dependent myofibrillar ATPase. Together, these findings support the hypothesis that PKC activation is involved in the adenosine receptor-dependent slowing of cross-bridge cycling. Because R-PIA-dependent PKC-ε translocation data shows only a coincidence with the observed decrease in cross-bridge cycling, the exact mechanism responsible for the decrease in cross-bridge cycling has yet to be definitively established. It is possible that adenosine receptor activation stimulates PKC-ε or another isoform of PKC (with a rapid transient), and this initiates a cascade of kinases or phosphatases ultimately leading to modification of a myofilament protein and subsequent decrease in V max .
Although the present experiments do not specifically address the physiological significance of the adenosine receptor-PKC-induced decrease in V max , we hypothesize that the decrease in V max is related to the ability of adenosine to protect the heart from ischemic damage (38) . We speculate that the 30% decrease in V max observed in the present study would significantly reduce ATP consumption because actin-myosin cycling during contraction accounts for 85% of ATP utilized in the rat myocardium (6) . This decrease in actomyosin ATPase and conservation of ATP would ensure adequate ATP levels for continued function of cellular ion pumps. Maintenance of ion homeostasis would attenuate intracellular Ca 2ϩ overload and subsequent damage due to activation of Ca 2ϩ -dependent proteases.
